Bataller A et al. Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. EHA 2023;Abstract S172.
Bazinet A et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: Phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 2022;9(10):e756-65. Abstract
Bernard E et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 2022;1(7). Abstract
DiNardo CD et al. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 2023;7(11):2378-87. Abstract
Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98(8):1307-25. Abstract
Grob T et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2022;139(15):2347-54. Abstract
Sallman DA et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study. J Clin Oncol 2023;41(15):2815-26. Abstract
Sallman DA et al. Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results. EHA 2022;Abstract S166.
Sallman DA et al. Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). ASH 2021;Abstract 246.
Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. ASCO 2020;Abstract 7507.
Savona MR et al. Prolonged survival in bi-allelic TP53-mutated (TP53mut) MDS subjects treated with oral decitabine/cedazuridine in the ASCERTAIN trial (ASTX727-02). ASH 2022;Abstract 854.
Savona MR et al. Prolonged survival observed in 133 MDS patients treated with oral decitabine/cedazuridine. International Congress on Myelodysplastic Syndromes 2021;Abstract P48.
Savona MR et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: A multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol 2019;6(4):e194-203. Abstract
Sekeres MA et al. Pevonedistat (PEV) + azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% marrow blasts: The randomized Phase 3 PANTHER trial. Blood 2021;138(Suppl 1):242. Abstract
Swoboda DM et al. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia 2022;36(4):1189-92. Abstract
Tashakori M et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 2022;140(1):58-72. Abstract
Zeidan AM et al. STIMULUS-MDS2 design and rationale: A phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncol 2023;19(9):631-42. Abstract
Zeidan AM et al. Primary results of stimulus-MDS1: A randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS). ASH 2022;Abstract 853.